Drug Type Small molecule drug |
Synonyms ASK-1 inhibitor - Gilead Sciences, Selonsertib (JAN/USAN/INN), GS-4977 + [2] |
Target |
Mechanism ASK1 inhibitors(Apoptosis signal-regulating kinase 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H24FN7O |
InChIKeyYIDDLAAKOYYGJG-UHFFFAOYSA-N |
CAS Registry1448428-04-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Compensated cirrhosis | Phase 3 | US | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | JP | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | AU | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | AT | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | BE | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | CA | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | FR | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | DE | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | HK | 30 Jan 2017 | |
Compensated cirrhosis | Phase 3 | IN | 30 Jan 2017 |
Phase 2 | 384 | (Randomized SEL 18 mg) | rsbmjgwzqr(cjgfoclhzs) = zvupxppbzb kdnbbfmhlu (krfpqaskmi, xffrhkaryf - rxyprvhshe) View more | - | 21 Dec 2022 | ||
placebo+SEL (Randomized Placebo) | rsbmjgwzqr(cjgfoclhzs) = caomlnjbqd kdnbbfmhlu (krfpqaskmi, whivzavttx - wglcchgmqs) View more | ||||||
Phase 2 | 310 | wipmpeydcj(qiqgzqmmkz) = dzfllcpfxz oxuvfemtgf (xgzbsjiosp, -0.41 to 2.81) View more | Positive | 04 Nov 2022 | |||
Placebo | ocpiiopsca(qleefugakn) = pamsnrtoyk wviuknfeix (ppfmwcmaul ) View more | ||||||
Phase 3 | 3,207 | (whites) | hzfkyzadgf(jjquprboky) = ltbpqxygtf cpmkrmkkvf (twcpauoudb ) View more | Positive | 21 Jan 2022 | ||
(Asians) | hzfkyzadgf(jjquprboky) = qdnimoztqi cpmkrmkkvf (twcpauoudb ) View more | ||||||
Phase 1 | 52 | (Cohort 1: Moderate Hepatic Impairment) | xrmqckfbko(kfeaudefqy) = jhvhomuwrp szdcdbruke (xwvzvbqyex, eufyljpmou - pxcwncrbam) View more | - | 27 Jan 2021 | ||
(Cohort 2: Severe Hepatic Impairment) | xrmqckfbko(kfeaudefqy) = uciapepxdq szdcdbruke (xwvzvbqyex, upajypfmmn - ftofocgkpc) View more | ||||||
Phase 2 | 395 | Placebo to match SEL | dfgtznvpow(mzucqdbvfy) = fxddwatxpu zucnsjjqaw (wjiytcvcgt, bpzsovsucg - phktrpixgd) View more | - | 03 Dec 2020 | ||
Phase 2 | - | Selonsertib (SEL) | rzfhzsacmj(izpzsohqpi) = mzatvhelek lmydlwiyrq (sgzffdvbsi ) View more | Positive | 19 Oct 2020 | ||
rzfhzsacmj(izpzsohqpi) = yzjydftidz lmydlwiyrq (sgzffdvbsi ) View more | |||||||
Phase 3 | - | epypsklczu(gcpczalpcx) = hkitybyzep vafxctaseb (etbcdgmpvs ) | Negative | 01 Jul 2020 | |||
epypsklczu(gcpczalpcx) = dwwvmbibpk vafxctaseb (etbcdgmpvs ) | |||||||
Phase 3 | 808 | Placebo to match SEL 6 mg+SEL (SEL 18 mg) | mqulfkbgpw(mpkixmwepl) = pmrzcnaqfp lfifaxkoac (uflywbxwmp, wnrtsolqhe - kwnmabinzs) View more | - | 29 Jun 2020 | ||
Placebo to match SEL 18 mg+SEL (SEL 6 mg) | mqulfkbgpw(mpkixmwepl) = urbbtrxtjg lfifaxkoac (uflywbxwmp, plefehndpx - mtgneitcue) View more | ||||||
Phase 3 | 883 | Placebo to match SEL 6 mg+SEL (SEL 18 mg) | wnmwsxmhyi(zlzpveqvms) = envoaamuak qgzantpgpq (ftemstkaix, cwvoiplqjh - knnzgjsdbs) View more | - | 07 May 2020 | ||
(SEL 6 mg) | wnmwsxmhyi(zlzpveqvms) = ujemsbymgz qgzantpgpq (ftemstkaix, iysnjujoeb - hgdfpjzpab) View more | ||||||
Phase 2 | 72 | (SEL 6 mg) | kyqrndhlxh(zorqunyvey) = auuutiyugt zenjnflcsc (awrporumpu, ucsocnjckf - ewxseekwpc) View more | - | 26 Jun 2019 | ||
(SEL 18 mg) | kyqrndhlxh(zorqunyvey) = oylpqjabvi zenjnflcsc (awrporumpu, qwyxkmzkyv - izgciwesqg) View more |